Exploristics is now part of MMS

Bringing new depth to study design through integrated analytics and modeling

We look forward to delivering even greater value… through optimized strategies that reduce the overall time and cost burden in drug development.
Chris Schoonmaker
Chief Operating Officer at MMS

Exploristics, the Northern Ireland-based biostatistics and data science company, has officially joined MMS. This integration includes KerusCloud®, a leading trial simulation platform that strengthens our ability to support complex development programs.

Expanded Capabilities for Sponsors

With the addition of the Exploristics team, MMS has enhanced its European footprint and added greater depth in statistical innovation and clinical trial simulation. The KerusCloud platform allows sponsors to explore trial scenarios in advance and improve the likelihood of regulatory success while reducing unnecessary cost and delay.

Our combined expertise supports sponsors through early-phase planning, strategic design selection, and regulatory readiness across multiple regions.

Exploristics visitors are invited to explore how our combined teams deliver on complex clinical development challenges.

A Stronger Future Together

With KerusCloud and MMS biometrics teams fully aligned, the same focus on modeling, simulation, and quality remains. Now, it is paired with deeper regulatory strategy and full-service biometrics. Sponsors working with the Exploristics team can expect the same support they know, with added global infrastructure and strategic consulting capabilities from MMS.

Together, we remain focused on building high-quality submissions, designing successful trials, and meeting the growing demands of clinical research with clarity and consistency.

Let us know how we can support your next project

Suggested For You

webinar

December 4th, 2025

Writing with Quality Control in Mind: A Cross-functional Approach 

webinar

June 26th, 2025

De-Risking Development with Specialized Data Strategies: From Trial Design to Submission

perspectives

November 4th, 2025

4 Key Takeaways from the EMA - Health Canada Joint Review Process and Evaluation of Its Efficiency

perspectives

October 28th, 2025

New Updates on Clinical Trial Transparency and Regulatory Requirements: A Comprehensive Overview 

webinar

October 21st, 2025

A Practical Guide to Expedited Regulatory Pathways

perspectives

October 21st, 2025

Shaping Clinical Development Through Writing: Francesca’s Journey at MMS 

news

October 16th, 2025

MMS Named Finalist in the Fierce Life Sciences Innovation Awards for KerusCloud® Clinical Trial Simulation Platform 

perspectives

October 14th, 2025

CRO Partnerships and Biotech Agility: How Smaller Sponsors Gain Speed in Clinical Development  

perspectives

October 7th, 2025

From Academia to Building Medical Writing Partnerships: Jessica Murdock’s MMS Story  

news

October 2nd, 2025

MMS Announces Its Role in Supporting Gates Ventures and the GNPC to Deliver One of the World's Largest Proteomic Datasets for Neurodegenerative Diseases

perspectives

September 30th, 2025

Ready by Design: Endpoints, Feasibility, and Scenario Testing

news

September 24th, 2025

MMS Named Finalist in Citeline’s 2025 Scrip Awards for Best Contract Research Organization (CRO) – Specialist Providers